Clinical implications of pharmacogenetics for glaucoma therapeutics

Pharmacogenomics Journal

Volumn 3, Issue 4, 2003, Pages 197-201

  McLaren, N C ^a   Moroi, S E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; COCAINE; DRUG METABOLIZING ENZYME; EPHEDRINE; LATANOPROST; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PROSTAGLANDIN F; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; TIMOLOL; TRAVOPROST;

ARTICLE; COMORBIDITY; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; ECONOMIC ASPECT; EYE PROTECTION; GENE EXPRESSION; GENE TARGETING; GLAUCOMA; HEALTH INSURANCE; HUMAN; INTRAOCULAR PRESSURE; MYDRIASIS; OPTIC NERVE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

GLAUCOMA; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0141813386     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500181     Document Type: Article

References (31)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-393.
2. Yoles E, Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol 1998; 42: 367-372.
3. Anonymous. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130: 429-440.
4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713.
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M and Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279.
6. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-1953.
7. Anonymous. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998; 126: 498-505.
8. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-484.
9. Grant WM. Tonographic method for measuring the facility and rate of aqueous flow in human eyes. Arch Ophthalmol 1950; 44: 204-214.
10. Camras CB, Minckler D. Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications. Am J Ophthalmol 2000; 129: 87-89.
11. Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999; 106: 1024-1029.
12. Chen KK, Poth EJ. Racial differences as illustrated by the mydriatic action of cocaine, euphthalmine, and ephedrine. J Pharmacol Exp Ther 1929; 36: 429-445.
13. Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J Pharmacol Exp Ther 1976; 197: 79-88.
14. Salminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta Ophthalmol Suppl 1985; 173: 15-18.
15. Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002; 3: comment 2007.
16. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286-1293.
17. Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol 2000; 130: 441-453.
18. Small KM, Wagoner LE, Levin AM, Kardia SLR, Liggett SB. Synergistic polymorphisms of beta-1 and α2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-1142.
19. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49: 369-379.
20. Vessell ES. Pharmacogenetic perspectives gained from twin and family studies. In: Kalow W (ed). Pharmacogenetics of Drug Metabolism. Permagon Press: New York, 1992
21. Brubaker RF. Chapter 9, Clinical measurements of aqueous dynamics: implications for addressing glaucoma. In: Civan MM (ed.). The Eye's Aqueous Humor: From Secretion to Glaucoma. Academic Press: San Diego, 1998.
22. Wax MB, Molinoff PB. Distribution and properties of beta-adrenergic receptors in human iris-ciliary body. Invest Ophthalmol Vis Sci 1987; 28: 420-430.
23. Moroi SE, McLaren NC. β-Adrenergic receptors in human ciliary epithelium and regulation by dexamethasone. Invest Ophthalmol Vis Sci CD-ROM, Annual Meeting Abstract Program, 2002; Abstract #4100.
24. Bylund DB, Chacko DM. Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue homogenates. Invest Ophthalmol Vis Sci 1999; 40: 2299-2306.
25. Huang Y, Gil DW, Vanscheeuwijck P, Stamer WD, Regan JW. Localization of alpha 2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Invest Ophthalmol Vis Sci 1995; 36: 2729-2739.
26. Moroi SE, Mittal RD, Grewal NK, Thompson DA. Molecular and pharmacological characterization of α2-adrenergic receptor subtypes in human ciliary body, isolated ciliary epithelium, and a NPE cell line. Invest Ophthalmol Vis Sci (Abstract Book) 1998; 39: S804.
27. Moroi SE, Hao Y, Sitaramayya A. Nitric oxide attenuates alpha(2)-adrenergic receptors by ADP-ribosylation of G(i)alpha in ciliary epithelium. Invest Ophthalmol Vis Sci 2001; 42: 2056-2062.
28. Moroi SE, McLaren NC, Downs CA, Musch DC, Richards JE. Single nucledotide polymorphisms in the β2-adrenergic receptor gene in patients with glaucoma. Invest Ophthalmol Vis Sci (Abstract Issue) 2001; 42: S564.
29. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345: 1030-1035.
30. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97: 10483-10488.
31. Gungor K, Beydagi H, Bekir N, Arslan C, Suer C, Erbagci I et al. The impact of acute dynamic exercise on intraocular pressure: role of the beta 2-adrenergic receptor polymorphism. J Int Med Res 2002; 30: 26-33.